RENOVARO INC. Renovaro Inc. Share Price Börse Stuttgart
Equities
2Q5
US29350E1047
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.477 EUR | +11.89% |
|
+6.45% | -52.29% |
| 06-14 | Renovaro Says Investors Commit $10 Million Additional Equity | MT |
| 05-24 | Renovaro, Amsterdam UMC Cancer Center Plan to Form Joint Venture for Cancer Immunotherapy | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | - | Capitalization | 34.41M 32.07M 2.71B |
|---|---|---|---|---|---|
| Net income 2022 | -113M -105M -8.9B | Net income 2023 | -39M -36.34M -3.07B | EV / Sales 2022 | - |
| Net cash position 2022 | 1.99M 1.85M 157M | Net Debt 2023 | 3.9M 3.64M 307M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.89
x | P/E ratio 2023 |
-0.8
x | Employees | 12 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 74.45% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +11.89% | ||
| Current month | +16.85% | ||
| 1 month | +16.85% | ||
| 3 months | +48.91% | ||
| 6 months | -34.30% | ||
| Current year | -52.29% |
1 month
1.28
1.50
Current year
1.013.08
1 year
0.494.52
3 years
0.498.95
5 years
0.4914.50
10 years
0.4914.50
| Managers | Title | Age | Since |
|---|---|---|---|
Mark Dybul
CEO | Chief Executive Officer | 60 | 22/01/18 |
Lester Russell
CTO | Chief Tech/Sci/R&D Officer | - | 20/08/23 |
Greg Duczynski
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregg Alton
BRD | Director/Board Member | 58 | 31/12/19 |
Avram Miller
BRD | Director/Board Member | - | 10/10/23 |
James Sapirstein
BRD | Director/Board Member | 63 | 05/03/18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/06/24 | 1.498 | +13.48% | 0 |
| 14/06/24 | 1.32 | +2.64% | 0 |
| 13/06/24 | 1.286 | -4.17% | 0 |
| 12/06/24 | 1.342 | +2.29% | 0 |
| 11/06/24 | 1.312 | +11.95% | 0 |
Delayed Quote Börse Stuttgart, June 17, 2024 at 04:19 pm
More quotes
Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.
| 1st Jan change | Capi. | |
|---|---|---|
| +16.86% | 124B | |
| +19.22% | 112B | |
| +3.52% | 22.94B | |
| -11.33% | 17.02B | |
| -16.50% | 16.88B | |
| -39.57% | 16.87B | |
| +3.13% | 13.63B | |
| +22.26% | 11.61B | |
| +108.57% | 10.31B |
- Stock Market
- Equities
- RENB Stock
- 2Q5 Stock
